The stock has a 52-week-high of $58.72 and a 52-week-low of $23.77. About Us The updated guidance reflects management's confidence in the long-term opportunity in PDP, as well as the massive growth opportunity from the potential approval of Nuplazid for DRP patients. ACADIA to Host Conference Call and Webcast on Thursday, May 7, 2020 , at 4:30 p.m. … This could drive the stock price higher, and it would create new avenues for top-line growth. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. Here's why that could continue.Nuplazid's dementia-related psychosis data stole the show at a major scientific conference yesterday.Unexpected phase 3 clinical trial data has investors smiling.Acadia's flagship drug notched a key late-stage win today.Great Q2 results powered by strong momentum for antipsychotic drug Nuplazid have investors fired up.Shares slump after the drugmaker releases bummer clinical news.The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month.The company's comeback story continued to gain momentum last month.The pharma company was an easy target for Mr. Market during last month's sell-off, but it appears well positioned for a rebound in 2019.Shares rebound after the company announces the pricing details of its common stock offering.Shares take a dive after management announces a fresh capital raise. That still represents 28% sales growth year over year. Its current ratio -- a measure of liquidity -- is 7.2, meaning it has a lot of short-term asset value respective to the value of its short-term liabilities.
If the outcome is positive, Acadia will submit a supplemental New Drug Application (sNDA) for the use of Nuplazid for treatment of MDD. Its investment in online tools will optimize its approach to sales, marketing, and medical education in this new environment and continue to drive top-line growth throughout the year. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. CEO Steve Davis noted that Acadia sees "continued growth in Nuplazid this year, and we remain confident in driving the long-term market opportunity in PDP. As mentioned, Acadia quickly adopted a virtual presence, incorporating a portal that provides healthcare providers with promotional and educational material, supporting the shift into telemedicine, and engaging with patients via online tools.The company is supporting its patients by continuing to deliver Nuplazid directly to patients' homes or through long-term care pharmacies and facilities, providing an uninterrupted supply of medicine even during challenging times created by COVID-19. Scientific Publications. Acadia's assets exceed its liabilities. The gross-to-net adjustment -- which accounts for pricing changes such as discounts and rebates -- was 25.4% for Q1 2020. Cumulative Growth of a $10,000 Investment in Stock AdvisorIs Acadia Pharmaceuticals a Buy?
Acadia Pharmaceuticals' track record of success and strong pipeline offers an attractive long-term opportunity for investors, especially at a depressed price. This collaboration provides Acadia with a portfolio of early-stage clinical candidates that will complement the current pipeline of CNS therapies and help build its long-term growth strategy. Analysts are bullish, setting an average price target of $59.00, with a range of $41 to $74. This newly created position will allow Acadia to source and create new business opportunities to expand on its innovative pipeline.Schneyer comes to the job as a former vice president of business development at Pfizer's Upjohn division, and his nine-plus years of experience -- overseeing strategic transactions including licensing agreements, product acquisitions and divestitures, collaborations, and company acquisitions -- will be quite valuable to Acadia over the long term. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. This will allow it to develop and commercialize drug candidates that target a specific receptor, muscarinic M1, to help treat various central nervous system (CNS) disorders. Retirement It has plenty of cash to operate, with $651.4 million in cash and investments. Investing Basics This value is in line with the broader biotechnology industry's average of 6.8. The results of this study are expected to be announced during Q3. Returns as of 09/04/2020. Its valuation gives Acadia a price-to-sales (P/S) ratio of 21, which is overvalued compared to its peers Acadia Pharmaceuticals is 99.3% institutionally owned, which suggests that investors like what they see in the stock.
See you at the top!
Company Information. This number is generally highest in Q1 due to an annual reset for Medicare Part D patients.During Q1, management has pivoted from in-person to virtual education and engagement, revising its net sales guidance down somewhat -- to $420 million to $450 million, from $440 million to $470 million. Management's strategic vision remains the same; in 2020, plans are to drive growth of Nuplazid, deliver on DRP, and develop treatment options for patients. Stock Market On May 7, Acadia announced that it had entered into a licensing agreement and research collaboration with Vanderbilt University. At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. Personal Finance On May 26, Acadia announced positive feedback from the U.S. Food and Drug Administration (FDA) on its strategy to combine two phase 3 clinical trial studies, called CLARITY-2 and CLARITY-3, for evaluating Nuplazid for treatment of major depressive disorder (MDD). In the most recent quarter, 126 institutional holders increased positions, 37 opened new positions, and 63 sold off positions.